Annexon, Inc. ANNX 深 沪
已收盘 02-06 16:00:00 美东时间
5.705
+0.075
+1.33%
华盛通- 最 高7.18
- 今 开5.93
- 成交量 171.46万股
- 最 低 4.545
- 昨 收 5.63
- 总市值 22.00万
- 52周最高 7.18
- 市盈率 静 --
- 换手率 4446.10%
- 52周最低 0.00
- 委 比 -10.66%
- 总股本 3.86万
- 历史最高 7.18
- 量 比 1.02
- 振 幅 46.80%
- 历史最低 0.00
- 每 手 1
- 风险率 1.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alpha Buying: Managing Biotech Risk With Insider Clues
Biotech stocks have a way of making smart people do dumb things. It starts inno...
01-16 00:32
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
Dr. Lloyd Clark, a资深眼科专家，加入Annexon领导其眼科创新项目。ANX007在治疗干性黄斑变性伴地理萎缩的三期试验ARCHER II中展现出显著视力保护效果，预计2026年下半年公布顶线数据。
2025-06-18 20:05
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
Douglas Love, president and CEO of Annexon, Inc., will present at the Jefferies Global Healthcare Conference on June 4, 2025. A live webcast and replay will be available on Annexon's website. The company focuses on developing therapies to treat neuroinflammatory diseases targeting the classical complement pathway.
2025-05-29 20:05
Cantor Fitzgerald Reiterates Overweight on Annexon
Cantor Fitzgerald analyst Josh Schimmer reiterates Annexon (NASDAQ:ANNX) with a Overweight.
2024-09-10 00:53
Annexon Presents Phase 2 ARCHER Data On Protection Of Vision And Photoreceptors With ANX007 In GA At The Retina Society 57th Annual Meeting And 24th Euretina Congress
Only Program that has Demonstrated Significant Vision Protection in Standard and Low Light Conditions and Significant Preservation of Photoreceptors in the Fovea Region Critical for Visual Acuity ARCHER II Phase 3
2024-09-09 20:03
